Objectives: Sample size calculation (SSC) is a pivotal step in clinical trial conception and design. Herein, we describe the frequency with which oncology phase III trials report the parameters required for SSC.
Materials and methods: We systematically searched for phase III trials published in 6 leading journals, which were accompanied by editorials from January 2008 to October 2011. Two blinded investigators extracted required and optional parameters for SSC according to the primary endpoint.
Results: We retrieved 140 eligible phase III trials. The median target sample size was 596 subjects (50 to 40,000); in 66.4% of cases, the number of enrolled subjects was at least 90% of the target. The primary endpoint was a continuous variable in 5.7%, categorical in 30.0%, and a time-to-event variable in 64.3% of phase III trials. Although nearly 80% reported a target sample size, only 27.9% of the trials provided all the required parameters for proper SSC. The most commonly reported parameters for sample size computation were α (93.6%) and β (90.7%) errors. The parameters least reported were the expected outcomes in the control or experimental groups, each provided in only 57.9% of trials.
Conclusions: The quality of SSC reporting in phase III cancer trials is poor. Such incomplete reporting may compromise future study designs, pooling of data, and interpretation of results. Lack of transparency in SSC reporting may also have ethical implications.
Bariani GM, de Celis Ferrari AC, Hoff PM, Krzyzanowska MK, Riechelmann RP. Bariani GM, et al. J Clin Oncol. 2013 Jun 20;31(18):2289-95. doi: 10.1200/JCO.2012.46.6706. Epub 2013 Apr 29. J Clin Oncol. 2013. PMID: 23630201
Curran D, Sylvester RJ, Hoctin Boes G. Curran D, et al. Eur J Surg Oncol. 1999 Jun;25(3):244-50. doi: 10.1053/ejso.1998.0635. Eur J Surg Oncol. 1999. PMID: 10336801
Barton S, Peckitt C, Sclafani F, Cunningham D, Chau I. Barton S, et al. Eur J Cancer. 2015 Dec;51(18):2732-9. doi: 10.1016/j.ejca.2015.08.030. Epub 2015 Nov 19. Eur J Cancer. 2015. PMID: 26608121 Review.
Thezenas S, Duffour J, Culine S, Kramar A. Thezenas S, et al. Eur J Cancer. 2004 May;40(8):1244-9. doi: 10.1016/j.ejca.2004.01.008. Eur J Cancer. 2004. PMID: 15110889
Lee JJ, Feng L. Lee JJ, et al. J Clin Oncol. 2005 Jul 1;23(19):4450-7. doi: 10.1200/JCO.2005.03.197. J Clin Oncol. 2005. PMID: 15994154 Review.
Nadler MB, Wilson BE, Desnoyers A, Valiente CM, Saleh RR, Amir E. Nadler MB, et al. Sci Rep. 2024 Jan 3;14(1):459. doi: 10.1038/s41598-023-50694-0. Sci Rep. 2024. PMID: 38172190 Free PMC article.
Haslam A, Olivier T, Prasad V. Haslam A, et al. ESMO Open. 2023 Feb;8(1):100779. doi: 10.1016/j.esmoop.2022.100779. Epub 2023 Feb 1. ESMO Open. 2023. PMID: 36736072 Free PMC article. Review.
Tulka S, Knippschild S, Funck S, Goetjes I, Uluk Y, Baulig C. Tulka S, et al. PLoS One. 2021 Jun 4;16(6):e0252640. doi: 10.1371/journal.pone.0252640. eCollection 2021. PLoS One. 2021. PMID: 34086796 Free PMC article.
Weir IR, Tian L, Trinquart L. Weir IR, et al. Biostatistics. 2021 Jan 28;22(1):82-96. doi: 10.1093/biostatistics/kxz018. Biostatistics. 2021. PMID: 31175828 Free PMC article.
Jachno K, Heritier S, Wolfe R. Jachno K, et al. BMC Med Res Methodol. 2019 May 16;19(1):103. doi: 10.1186/s12874-019-0749-1. BMC Med Res Methodol. 2019. PMID: 31096924 Free PMC article. Review.